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Abstract
Background: Acute lymphoblastic leukemia is the most common malignant cancer in childhood. The signs and
symptoms of childhood cancer are difficult to recognize, as it is not the first diagnosis to be considered for
nonspecific complaints, leading to potential uncertainty in diagnosis. The aim of this study was to perform
proteomic analysis of serum from pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) to identify
candidate biomarker proteins, for use in early diagnosis and evaluation of treatment.
Methods: Serum samples were obtained from ten patients at the time of diagnosis (B-ALL group) and after
induction therapy (AIT group). Sera from healthy children were used as controls (Control group). The samples were
subjected to immunodepletion, affinity chromatography with α-D-galactose-binding lectin (from Artocarpus incisa
seeds) immobilized on a SepharoseTM 4B gel, concentration, and digestion for subsequent analysis with nano-UPLC
tandem nano-ESI-MSE. The program ExpressionE was used to quantify differences in protein expression between
groups.
Results: A total of 96 proteins were identified. Leucine-rich alpha-2-glycoprotein 1 (LRG1), Clusterin (CLU), thrombin
(F2), heparin cofactor II (SERPIND1), alpha-2-macroglobulin (A2M), alpha-2-antiplasmin (SERPINF2), Alpha-1 antitrypsin
(SERPINA1), Complement factor B (CFB) and Complement C3 (C3) were identified as candidate biomarkers for early
diagnosis of B-ALL, as they were upregulated in the B-ALL group relative to the control and AIT groups. Expression
levels of the candidate biomarkers did not differ significantly between the AIT and control groups, providing further
evidence that the candidate biomarkers are present only in the disease state, as all patients achieved complete
remission after treatment.
Conclusion: A panel of protein biomarker candidates has been developed for pre-diagnosis of B-ALL and also
provided information that would indicate a favorable response to treatment after induction therapy.
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Background
Acute lymphoblastic leukemia (ALL) is the most com-
mon malignant cancer in childhood, and is responsible
for approximately 25 % of all childhood cancers and
72 % of all cases of pediatric leukemia [1]. The current
standards for diagnosis of ALL integrate the study of cell
morphology, immunophenotyping, and genetics/cyto-
genetics, as described in the classification of lymphoid
cancers published by the World Health Organization
(WHO) in 2008 [2]. Of lymphoid cancers, as designated
using the most recent WHO classification, the purely
leukemic presentation, B-lineage ALL (85 %) is the most
common [3]; it will be addressed in this study. The signs
and symptoms of childhood cancer are very challenging
to identify, as it is not the first diagnosis to be consid-
ered for nonspecific complaints, leading to potential un-
certainty in diagnosis. Moreover, children showing the
first signs of cancer frequently do not appear severely ill,
which may delay diagnosis. In addition, childhood can-
cer can mimic other common childhood diseases and
even normal developmental physiological processes [4].
Measures to improve cancer incidence rates in adults in-
clude prevention of exposure to known carcinogenic risk
factors, such as smoking, but environmental factors play
a very small role in the development of childhood can-
cers. Thus, primary prevention measures are not effect-
ive in averting the development of cancer in this age
group, and secondary prevention, i.e. early diagnosis, is
therefore essential [5]. In the specific case of ALL, early
diagnosis and treatment increase the chances of a cure
[4]. Affinity chromatography with α-D-galactose-binding
lectin from Artocarpus incisa immobilized on a Sephar-
ose™ 4B gel, combined with identification and quantifica-
tion of glycoproteins by mass spectrometry, are excellent
tools for comparative serum studies. The biomarker
pipeline is commonly viewed as a series of preclinical
phases: biomarker discovery, and verification before the
final clinical evaluation. The comparative analysis results
in a list of hundreds of proteins that are differentially-
expressed between healthy and diseased samples [6]. In
this study, the preclinical phase of biomarker discovery
was applied and a proteomic analysis of serum samples
from pediatric patients with B-ALL was performed, to
analyze levels of glycoprotein expression, with the aim of
identifying biomarkers to aid in the early diagnosis of B-
ALL and to assess the response to induction therapy.
Methods
Patients and samples
Serum samples were collected from ten pediatric pa-
tients with B-ALL at diagnosis and after induction
therapy. These patients were diagnosed based on mor-
phological, immunophenotypic, and genetic tests. The
study population was composed mainly of children from
the lower middle class, who attended a reference hos-
pital for the diagnosis and treatment of childhood can-
cers in the State of Ceará -Brazil. The mean age of the
patients was 6.15 years (n = 10); the average age of fe-
male patients was 3.8 years (n = 6) and that of male pa-
tients was 3.5 years (n = 4). All patients were assigned as
low risk (LR) when aged from 1 to 9 years old, with a
white blood cell (WBC) count <50 × 109/L, and no CNS
involvement. The risk stratification and chemotherapy
were performed according to the protocol of the Brazilian
Group for Treatment of Childhood Leukemia (GBTLI-
LLA-2009). All patients experienced complete clinical and
morphological remission and are presently surviving.
The serum samples used as controls were obtained
from ten non-leukemic pediatric patients. All samples
were stored at −80 °C until use and concentrations
were determined using a Nanovue Plus™ apparatus (GE
Healthcare, Uppsala, Sweden). The study was conducted
with the approval of the Research Ethics Committee at the
Hospital Infantil Albert Sabin, associated with the
Secretary of Health of the State of Ceará.
Serum preparation
For each sample, high-abundance human serum albumin
(HSA) and immunoglobulin G (IgG) proteins were de-
pleted using a HiTrap™ Albumin & IgG Depletion col-
umn (GE Healthcare) on an ÄKTA purifier 10 Fast
protein liquid chromatography (FPLC) system (GE
Healthcare) according to the manufacturer’s instructions.
After removal of high-abundance proteins, the flow-
through fractions were collected and stored at −80 °C
until use.
Lectin affinity chromatography
The serum-free high-abundance proteins were thawed,
centrifuged for 15 min at 12,000 × g at 8 °C, filtered
through a 0.22-μM membrane (Vertipure™ PVDF syringe
filters, Veritical) and applied to a 5-mL column packed
with Sepharose-Frutalin, prepared as mentioned previ-
ously, in a XK16 column on an ÄKTA purifier 10 FPLC
system (GE Healthcare). The column was washed with
five CV of buffer A (20 mM Tris–HCl, pH 7.4), and the
lectin-bound proteins were eluted with four CV of elu-
tion buffer B (20 mM Tris–HCl, pH 7.4, with 0.2 M gal-
actose). The eluted protein solution was dialyzed and
concentrated by spinning at 8000 × g (Vivaspin® 6, with a
molecular weight cut-off of 3 kDa, GE Healthcare), and
used for further analyses.
Proteomic analysis
Briefly, each sample containing 50 μg of protein was de-
natured with 0.2 % RapiGest™ SF (Waters, Milford,
USA), reduced with 10 mM dithiothreitol, alkylated with
10 mM iodoacetamide, and enzymatically digested with
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trypsin (Promega, Madison, WI, USA). At the end of this
process, the samples were centrifuged and the super-
natant was transferred to new vials, to which 5 μL of in-
ternal standard, alcohol dehydrogenase (ADH, 50 fmol,
access code P00330 in SwissProt) and 85 μL of 3 %
acetonitrile solution with formic acid 0.1 % were added.
The final glycoprotein and ADH concentrations were es-
timated to be 250 ng/μL and 25 fmol/μL, respectively, in
a final volume of 200 μL. The quantitative and qualita-
tive nano-UPLC tandem nano-ESI-MSE experiments
were performed on digested samples using peptide
reversed-phase chromatography with 3 to 40 % (v/v) of
acetonitrile containing 0.1 % formic acid for 90 min, main-
tained at a flow rate of 600 nL/min for 100 min in a
nanoACQUITY UPLC core system. A nanoACQUITY
C18 UPLC BEH 1.7 μm, 100 μm× 10 cm reversed-phase
column was used in conjunction with an SCX 5 μm,
180 μm× 23 mm pre-column. All analyses were per-
formed with electrospray ionization in positive ion ESI(+)
mode and a NanoLockSpray source. Data-independent ac-
quisition (MSE) was performed with a SYNAPT HDMS
G1 mass spectrometer (Waters, Manchester, UK), pro-
grammed to automatically switch between standard MS
(3 eV) and high-energy collision MSE (12–50 eV), applied
to trap ‘T-wave’ CID (collision-induced dissociation) cells,
in the presence of argon gas. The transfer from the colli-
sion cell was adjusted to 1 eV, with 1 s, at both low and
high energy. After the time of flight analysis (TOF), m/z
50 to 3000 spectra were collected. However, the RF offset
of the quadrupole was set for efficient acquisition of LC/
MS data from m/z 300–3000, ensuring that any mass less
than m/z 300 observed in the LC/MSE data stemmed only
from the collision cell. Thus, the low-mass values were
known CID fragmentation products, not the result of
source fragmentation. For processing of spectra and data-
base searches, the Protein Lynx Global Server (PLGs)
package v. 2.4, containing the ExpressionE v. 2.4 program,
was used. The PLGs used a new algorithm to process raw
data obtained by MS using ion properties, i.e. retention
time, intensity of precursor/productions, and exact mass.
A label-free proteomic approach was used for the quanti-
tative analysis. Then the PLGs generated a list of all pre-
cursors and products. This list contained the mass of the
precursor and product ions for each peptide, to be
searched against the non-redundant proteins database,
UniProtKB/Swiss-Prot 57.1, under search conditions
based on taxonomy [Human (Homo sapiens)]. For each
protein, the program ExpressionE selected all correspond-
ing peptides from the samples and compared the inten-
sities of these for relative protein quantification. Using the
intensity of a peptide of known quantity, ADH, the pro-
gram performed self-standardization of data sets. Lists of
proteins were then filtered to show only those present in
all three repeated injections of each sample, from which
an output table was created. This table showed the names,
access codes, and expression levels of the proteins, and in-
dicated whether they were up-regulated ≥2-fold, down-
regulated ≤0.5-fold, or whether they did not show signifi-
cant differences between the groups (unchanged), 0.5< ex-
pression level <2.
Protein interaction network analysis
The differentially expressed proteins were used for path-
way analysis. Swiss-Prot accession numbers were inserted
into the Search Tool for the Retrieval of Interacting
Genes/Proteins (STRING) software, version 9.05, which is
available at http://string.embl.de/, with the following ana-
lysis parameters: Homo sapiens, confidence level 0.400–
0.900, using the active prediction method [7].
Results and discussion
Patient characteristics
The demographic and clinical data for the patients are
summarized in Table 1. To form the panel of candidate
proteins for early biomarkers and demonstrate their ex-
pression profiles, the pediatric patients were evaluated at
two different times: at diagnosis (B-ALL Group; n = 10)
and after induction therapy (AIT Group; n = 10). Sam-
ples of healthy children (Control Group; n = 10) were
obtained for comparison.
Reduction of dynamic range
The depletion of high-abundance proteins in serum,
HSA and IgG, followed by affinity chromatography with
the plant lectin Frutalin immobilized on Sepharose™ 4B
(Fig. 1), reduced the dynamic range and increased the
capacity to identify lower-abundance proteins. The
retained fraction (FR) peak containing the protein of
interest was concentrated and digested, for later analysis
by nano-LC-MS/MS.
Proteomic analysis
In the proteomic analysis, a total of 96 proteins were
identified. Leucine-rich alpha-2-glycoprotein 1 (LRG1),
Clusterin (CLU), thrombin (F2), heparin cofactor II
(SERPIND1), alpha-2-macroglobulin (A2M), alpha-2-
antiplasmin (SERPINF2), Alpha-1 antitrypsin (SER-
PINA1), Complement factor B (CFB) and Complement
C3 (C3) were over-expressed in the B-ALL compared to
the control and AIT groups, and were therefore identi-
fied as candidate biomarkers for early diagnosis of B-
ALL. The AIT group showed no significant differences
in the expression levels of these proteins, compared to
the control group, did not show any significant change
in the level of expression of these proteins, a fact that
further reaffirms the presence of these potential bio-
markers in a disease state, as all patients achieved
complete remission after treatment (Fig. 2).
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P1 M 3 L1 Common Absence of metaphases LR _ CR
P2 F 3 L1 Pre-B Absence of metaphases LR _ CR
P3 F 5 L1 Common 56,XX,+X,+4,+6,+8,+10,+11,+14,+17,+21,+mar/
46,XX
LR _ CR
P4 M 2 L1 Common 46,XY LR _ CR
P5 F 2 L1 Common 46,XX LR _ CR
P6 F 3 L1 Common 54,XX,+X,+6,+15,+15,+17,+18,+21,+21/46,XX LR _ CR
P7 F 5 L1 Common 47,XY,+21 c LR _ CR
P8 M 6 L1 Common Absence of metaphases LR _ CR
P9 F 5 L1 Pre-B 46, XX LR _ CR
P10 M 3 L1 Pre-B 46,XY LR _ CR
Code: Internal register assigned for the study; M Male, F Female, LR Low Risk, MRD Minimum Residual Disease, CR Complete remission
Fig. 1 Graphical representation of the affinity chromatography process on a Frutalin-immobilized column with Sepharose 4B, coupled with an
ÄKTA purifier 10 FPLC system. Peak I represents the non-retained fraction (FNR) and Peak II represents the retained fraction (FR). The fractions were
obtained after elution with their respective buffers: 20 mM Tris–HCl, pH 7.4, in0.15 M NaCl (Buffer A) and 0.2 M galactose and 20 mM Tris–HCl,
pH 7.4, in 0.15 M NaCl (Buffer B). The blue line represents absorbance at 280 nm and the red represents emission at 216 nm
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LRG1 was 2.16-fold upregulated in the B-ALL group
compared to the Control group. LRG1 is involved in cell
adhesion and development, protein-protein interaction,
and signal transduction. Studies have shown that it may
be a biomarker for ovarian cancer, pancreatic cancer,
oral squamous cell carcinoma [8, 9], and non-small cell
lung cancer [10]. CLU, also called apolipoprotein J, was
2.64-fold upregulated in the B-ALL group compared to
the control. CLU is expressed in a variety of tissues, with
a ubiquitous pattern of expression. It has a high sensitiv-
ity to external stress stimuli. It has been reported to
function in complement inhibition, clearance of cellular
debris, folding of denatured proteins (chaperone), and
regulation of cell death [11, 12]. Several studies have
shown that it is over-expressed in many serious physio-
logical conditions, including degenerative kidney disease
and various neurodegenerative conditions. CLU also
plays an important role in tumorigenesis and progres-
sion of many human cancers [13]. Higher levels of this
protein have been observed in the progression of pros-
tate cancer and renal carcinoma compared to normal
tissues [14, 15] and it was shown to be over-expressed in
anaplastic large cell lymphomas [16], ovarian cancer [17],
esophageal cancer [18], and colorectal cancer; it has also
been implicated in pre-diagnosis of colorectal cancer [19].
The accumulation of CLU protein is correlated with the
aggressiveness of certain breast tumors [20].
Our results also confirm the important relationship
between cancer and phenomena associated with blood
coagulation. Several studies have reported that approxi-
mately 50 % of patients with malignant disease and more
than 90 % of those that evolve to metastasis present evi-
dence of abnormalities in coagulation and/or fibrinolysis
[21–25]. Several of the proteins identified in this study,
such as F2, SERPINF2, SERPIND1, A2M, are known to
be involved in coagulation; here, they were found to be
overexpressed by 2.12-, 2.20-, 2.56- and 3.10-fold. Can-
cerous cells can activate the coagulation system directly,
by generating thrombin, or indirectly, by stimulating
mononuclear cells to express a variety of pro-coagulant
proteins [25]. These pro-coagulant factors are expressed
in cancerous cells, which results in the activation of co-
agulation factors VII and X [26, 27]. Cytokines released
from cancer cells trigger coagulant activity in mono-
cytes, platelets, and endothelial cells. The formation of
fibrin can occur in many types of cancer tissues, and fi-
brin matrix formation seems to favor protection of can-
cer cells from the immune system [28]. Although this
study reports over-expression of coagulation-associated
proteins in patients with B-ALL, which is a malignant
tumor of circulating cells, fibrinogen may not be in-
volved in immune protection of non-adherent cancers,
but may function as a promoter of the growth and
spread of cancer [26, 29, 30]. Some studies have reported
an association between hemostatic abnormalities and
gastric cancer [31, 32], and an association of cancer with
thrombotic events [33–38]. Other studies have shown
that blood levels of fibrinogen are correlated with ag-
gressiveness in gastric cancer [21, 35]. Kwon et al. [21]
reported that a single determination of coagulation
markers, in particular thrombin-antithrombin complex
(TAT), fibrin monomer, and D-dimer, is sufficient to de-
termine the prognosis and survival of patients with can-
cer. Over-expression of anticoagulant proteins may be
due to stimulation by the excess of thrombin in blood
[21]. Braoudaki et al. [39] reported differentially in-
creased expression levels of A2M in bone marrow
plasma samples in patients with ALL. In our study this
Fig. 2 Panel of candidate protein biomarkers for B-ALL. Blue columns represent the expression levels of the proteins in B-ALL patients at the time
of diagnosis in relation to the control. Green columns represent the expression levels of the proteins in B-ALL patients after induction therapy
(day 35) relative to controls. (*) (p < 0.05)
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protein was 3.1-fold upregulated in the serum of B-ALL
patients, and its level of expression decreased signifi-
cantly after induction therapy. Nevertheless, compared
with serum samples from control patients, no significant
changes in expression levels of A2M were observed. This
shows that A2M is in fact upregulated in patients with
B-ALL and can be considered both as a candidate bio-
marker of disease as well as for evaluation of the re-
sponse to induction therapy. Moreover, serum analysis is
less invasive than bone marrow biopsy [39].
Alpha-1 antitrypsin (SERPINA1) was 3.06-fold upregu-
lated compared to controls. SERPINA1 is a serum glyco-
protein that is synthesized primarily in the human liver
and in macrophages. It belongs to the serpin family,
which plays a central role in the control of degradation
of tissues through its inhibitory effect on neutrophil
elastase and other serine proteases, including trypsin,
chymotrypsin, cathepsin G, plasmin, thrombin, tissue
kallikrein, and activated factor X (FXa) [40–42]. Many
types of cancer cells have been shown to express and se-
crete alpha-1 antitrypsin [43–45]. In addition, high serum
levels of this protein have been reported in a number of
inflammatory diseases and in various malignancies, such
as hepatocellular carcinoma, multiple myeloma, pancre-
atic carcinoma, prostate carcinoma, primary carcinoma of
the lung, cervical carcinoma, gastric cancer, laryngeal can-
cer, nasopharyngeal carcinoma, breast cancer, and colorec-
tal cancer [45–52]. Some studies reported that levels of
this protein were correlated with cancer stage [47, 53–56].
A previous study of lung and prostate cancers, showed a
direct correlation between high serum levels of SERPINA1
and cancer stage. It has been also suggested that the main
source of the increase in blood levels of this protein in
cancer patients is the growth of cancer cells [47]. In a re-
cent survey, also of lung cancer and prostate cancer, a de-
crease in the serum levels of SERPINA1 was observed
several weeks after treatment, suggesting that it may be an
important indicator of the effectiveness of cancer treat-
ment [57].
Complement factor B (CFB) and Complement C3
(C3), which are both associated with the complement
system, were found to be 3.06- and 6.36-fold upregu-
lated. The complement system is an essential part of the
innate immune response that participates in the elimin-
ation of altered cells from the body. Due to the large
number of genetic and epigenetic alterations associated
with carcinogenesis, neoplastic transformation can in-
crease the ability of malignant cells to activate this sys-
tem [58], which may explain the over-expression of
these proteins, in agreement with other studies that re-
port the over-expression of complement proteins in pul-
monary cells [59, 60]. Although malignant cells often
develop mechanisms for protection against and resistance
to complement, recent research on the mechanisms regu-
lating complement activity demonstrated that the over-
expressed proteins showed inhibitory activity [61–63].
Therefore, the proteins found to be upregulated in this
study may be candidate biomarkers of B-ALL, because the
alteration in expression was observed only in cancer pa-
tients. This result is corroborated by the absence of
changes in expression levels of these proteins in the serum
of patients who underwent induction therapy and who ex-
perienced complete remission, as well as in healthy indi-
viduals from the control group.
Fig. 3 Interactome generated by STRING interaction database. Required confidence (score): medium confidence (0.400)
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All nine proteins identified found to be upregulated in
the B-ALL group showed evidence of interaction, as
shown by the protein interaction network generated by
the STRING interaction database (http://string-db.org/)
(Fig. 3). Some studies have shown that increased expres-
sion of thrombin is associated with leukemia, as well as
several other diseases [64, 65]. Similarly, as previously
mentioned, the increase in blood levels of SERPINA1 in
cancer patients is proportional to the growth of cancer
cells; a decrease is observed several weeks after chemo-
therapy. Because these proteins lack specificity for the
diagnosis of B-ALL if used in isolation, we suggest the
creation of panel of biomarker.
Conclusion
LRG1, CLU, F2, SERPIND1, A2M, SERPINF2, SER-
PINA1, CFB, and C3 were identified as candidate bio-
markers for early diagnosis of B-ALL; all were over-
expressed in the B-ALL group compared to the control
and AIT groups. The AIT group did not display any sig-
nificant changes in the expression levels of these pro-
teins, compared to the control group. All patients in the
AIT group achieved complete remission after treatment;
this indicates that these biomarkers are only present in
the disease state. These candidate biomarkers may im-
prove the pre-diagnosis of B-ALL, which is currently dif-
ficult to diagnose in the early stages; the biomarkers may
also provide key information on the response to treat-
ment after induction therapy. Further clinical studies are
necessary to determine whether over-expression of these
proteins is associated with development of acute symp-
toms in patients with suspected ALL. These markers
may help to determine response to treatment and to im-
prove the survival of children with this disease.
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